Will Ashworth

Will Ashworth

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

For Pinterest Stock, The Glass Is Still Half Full

Pinterest trails its social media peers when it comes to monetizing its users. If you own PINS stock, here’s why you shouldn’t be concerned.  

Senseonics Stock Looks Like It Is Going to Stay Rangebound for a While

It’s a risk to have one company account for much of your revenue. In the case of Senseonics, that’s a good thing for SENS stock. 

Focus On PIF, Not PIPE To See Where Lucid Group Stock Is Headed

Lucid Group saw its share price drop 10% due to a lockup expiry for PIPE shareholders. That’s not the biggest problem facing LCID stock.

Clover Health Stock Isn’t Going to $20 Anytime Soon, But It Still Might Be a Buy

Clover Health Investments trades near its $9.50 median price target for CLOV stock. Until more analysts buy into its story, caution is key. 

7 S&P 500 Dividend Stocks To Buy Yielding 4%  

There are 80 companies in the S&P 500 High Dividend Index ETF. Here are seven dividend stocks to buy from this exchange-traded fund that yield at least 4%.

Forget GameStop. Buy These 5 Stocks Instead

It's tempting to buy GameStop for big gains. However, for one share of GME stock, you could buy all five of these other stocks.  

7 Stocks To Buy To Bet on Underappreciated CEOs

We hear plenty of stories about overpaid CEOs. Here are seven stocks to buy whose CEOs aren’t but still manage to deliver for shareholders.

Why It’s Really Hard to Take Shiba Inu Seriously

Shiba Inu is testing support at 0.000007 cents. It’s hard to take the cryptocurrency seriously when it trades well below a penny per token.   

Sundial Growers Is Not Worth the Sum of All Its Parts

Add up all its investments and revenue streams and Sundial still isn’t worth $1.54 billion. Investors should pass on SNDL stock.

If You’re Long Clover Health Stock, Forget About Profits

CLOV stock is highly speculative, and potential buyers should focus on revenue growth and economies of scale.